Anika Therapeutics, Inc. (ANIK) Misses Q1 EPS by 3c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $25.58 -1.24%
Revenue Growth %: +9.6%
Financial Fact:
Net income: 8.95M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: +9.6%
Financial Fact:
Net income: 8.95M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q1 EPS of $0.14, $0.03 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $14.4 million versus the consensus estimate of $18.2 million.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Utah Medical Products (UTMD) Reports Q1 EPS of $1.10
- Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
